Reduced expressions of apoptosis-related proteins TRAIL, Bcl-2, and TNFR1 in NK cells of juvenile-onset systemic lupus erythematosus patients: relations with disease activity, nephritis, and neuropsychiatric involvement

被引:1
作者
Liphaus, Bernadete L. [1 ,2 ]
Silva, Simone C. [1 ]
Palmeira, Patricia [1 ]
Silva, Clovis A. [2 ,3 ]
Goldenstein-Schainberg, Claudia [3 ]
Carneiro-Sampaio, Magda [1 ]
机构
[1] Univ Sao Paulo, Fac Med, Lab Med Invest, Sao Paulo, Brazil
[2] Univ Sao Paulo, Fac Med, Pediat Rheumatol Unit, Inst Crianca, Sao Paulo, Brazil
[3] Univ Sao Paulo, Hosp Clin, Fac Med, Disciplina Reumatol, Sao Paulo, Brazil
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
基金
巴西圣保罗研究基金会;
关键词
anti-dsDNA; apoptosis; Bcl-2; Juvenile SLE; NK cells; nephritis; SLEDAI-2K score; TRAIL; NATURAL-KILLER-CELLS; MONONUCLEAR-CELLS; T-LYMPHOCYTES; INCREASED FAS; CLASSIFICATION; COMPLEMENT; AUTOIMMUNE; CRITERIA;
D O I
10.3389/fimmu.2024.1327255
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Lupus pathogenesis is mainly ascribed to increased production and/or impaired clearance of dead cell debris. Although self-reactive T and B lymphocytes are critically linked to lupus development, neutrophils, monocytes, and natural killer (NK) cells have also been implicated. This study assessed apoptosis-related protein expressions in NK cells of patients with juvenile-onset systemic lupus erythematosus (jSLE) and relations to disease activity parameters, nephritis, and neuropsychiatric involvement.Methods Thirty-six patients with jSLE, 13 juvenile dermatomyositis (JDM) inflammatory controls, and nine healthy controls had Fas, FasL, TRAIL, TNFR1, Bcl-2, Bax, Bim, and caspase-3 expressions in NK cells (CD3-CD16+CD56+) simultaneously determined by flow cytometry. Disease activity parameters included Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, erythrocyte sedimentation rate, C-reactive protein level, anti-double strain DNA antibody level, complement fractions C3 and C4 levels.Results Patients with jSLE had a profile of significantly reduced expression of TRAIL, Bcl-2, and TNFR1 proteins in NK cells when compared to healthy controls. Similar profile was observed in patients with jSLE with active disease, positive anti-dsDNA, nephritis, and without neuropsychiatric involvement. Patients with jSLE with positive anti-dsDNA also had reduced expression of Bax in NK cells when compared healthy controls and to those with negative anti-dsDNA. Yet, patients with jSLE with negative anti-dsDNA had reduced mean fluorescence intensity (MFI) of Bim in NK cells compared to healthy controls. Patients with jSLE with nephritis also had reduced MFI of Fas in NK cells when compared to those without nephritis. In addition, in patients with jSLE, the proportion of FasL-expressing NK cells directly correlated with the SLEDAI-2K score (rs = 0.6, p = 0.002) and inversely correlated with the C3 levels (rs = -0.5, p = 0.007). Moreover, patients with jSLE had increased NK cell percentage and caspase-3 protein expression in NK cells when compared to JDM controls.Conclusion This study extends to NK cells an altered profile of TRAIL, Bcl-2, TNFR1, Fas, FasL, Bax, Bim, and caspase-3 proteins in patients with jSLE, particularly in those with active disease, positive anti-dsDNA, nephritis, and without neuropsychiatric involvement. This change in apoptosis-related protein expressions may contribute to the defective functions of NK cells and, consequently, to lupus development. The full clarification of the role of NK cells in jSLE pathogenesis may pave the way for new therapies like those of NK cell-based.
引用
收藏
页数:10
相关论文
共 38 条
  • [1] POLYMYOSITIS AND DERMATOMYOSITIS .1.
    BOHAN, A
    PETER, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (07) : 344 - 347
  • [2] Understanding systemic lupus erythematosus physiopathology in the light of primary immunodeficiencies
    Carneiro-Sampaio, Magda
    Liphaus, Bernadete Lourdes
    Jesus, Adriana Almeida
    Silva, Clovis Artur A.
    Oliveira, Joao Bosco
    Kiss, Maria Helena
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2008, 28 (Suppl 1) : S34 - S41
  • [3] Increased apoptosis and expression of FasL, Bax and caspase-3 in human lupus nephritis class II and IV
    Cui, Ji-Hong
    Qiao, Qing
    Guo, Ying
    Zhang, Ya-Qing
    Cheng, Hong
    He, Fu-Rong
    Zhang, Jing
    [J]. JOURNAL OF NEPHROLOGY, 2012, 25 (02) : 255 - 261
  • [4] TRAIL mRNA expression in peripheral blood mononuclear cells of Egyptian SLE patients
    El-Karaksy, Safaa Mostafa
    Kholoussi, Naglaa Mohamed
    Shahin, Rasha Mohamad Hosny
    Abou E-Ghar, Mona Mohsen
    Gheith, Rasha El-Sayed
    [J]. GENE, 2013, 527 (01) : 211 - 214
  • [5] The regulation of FasL expression -: A distinguishing feature between monocytes and T lymphocytes/NK cells with possible implications for SLE
    Eneslätt, K
    Rantapää-Dahlqvist, S
    Uddhammar, A
    Sundqvist, KG
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2001, 21 (03) : 183 - 192
  • [6] Lack of NK cells in lupus patients with renal involvement
    ErkellerYuksel, FM
    Lydyard, PM
    Isenberg, DA
    [J]. LUPUS, 1997, 6 (09) : 708 - 712
  • [7] Gladman DD, 2002, J RHEUMATOL, V29, P288
  • [8] Features of 847 Childhood-Onset Systemic Lupus Erythematosus Patients in Three Age Groups at Diagnosis: A Brazilian Multicenter Study
    Gomes, Roberta C.
    Silva, Marco F.
    Kozu, Katia
    Bonfa, Eloisa
    Pereira, Rosa M.
    Terreri, Maria T.
    Magalhaes, Claudia S.
    Sacchetti, Silvana B.
    Marini, Roberto
    Fraga, Melissa
    Carvalho, Luciana M.
    Barbosa, Cassia M.
    Carneiro-Sampaio, Magda
    Silva, Clovis A.
    [J]. ARTHRITIS CARE & RESEARCH, 2016, 68 (11) : 1736 - 1741
  • [9] NK cells dysfunction in systemic lupus erythematosus: relation to disease activity
    Henriques, Ana
    Teixeira, Luis
    Ines, Luis
    Carvalheiro, Tiago
    Goncalves, Ana
    Martinho, Antonio
    Pais, Maria Luisa
    Pereira da Silva, Jose Antonio
    Paiva, Artur
    [J]. CLINICAL RHEUMATOLOGY, 2013, 32 (06) : 805 - 813
  • [10] Herrmann M, 1998, ARTHRITIS RHEUM-US, V41, P1241, DOI 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO